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Pyrophosphate ions are both inhibitors of HA formation and substrates for phosphatase enzymes. Unlike
polyphosphates their hydrolysis results simultaneously in the complete loss of mineral formation inhi-
bition and a localised elevation in orthophosphate ion concentration. Despite recent advances in our
knowledge of the role of the pyrophosphate ion, very little is known about the effects of pyrophosphate
on bone formation and even less is known about its local delivery. In this work we ﬁrst developed a self
setting pyrophosphate based calcium cement system with appropriate handling properties and then
compared its in vivo degradation properties with those of a non-pyrophosphate containing control.
Contrary to expectation, the presence of the pyrophosphate phase in the cement matrix did not inhibit
mineralisation of the healing bone around the implant, but actually appeared to stimulate it. In vitro
evidence suggested that enzymatic action accelerated dissolution of the inorganic pyrophosphate ions,
causing a simultaneous loss of their mineralisation inhibition and a localised rise in supersaturation with
respect to HA. This is thought to be a rare example of a biologically responsive inorganic material and
these materials seem to be worthy of further investigation. Bioceramics to date have mainly been limited
to orthophosphate, silicate and carbonate salts of calcium, here we report the successful application of a
pyrophosphate material as a degradable osteoconductive bone repair cement.
 2013 The Authors Published by Elsevier Ltd. . Open access under CC BY license.1. Introduction
Calcium orthophosphate based bone graft replacements have
been investigated as potential bone graft replacements since 1920
when tricalcium phosphate was injected into an animal model [1].
During the 70’s there was a concerted effort to develop new calcium
phosphate grafts based on tricalcium phosphate or hydroxyapatite
(HA)monoliths [2,3]. Despite 40 years of further research,HAhasnot
replaced autologous tissue as the surgical ‘gold-standard’. The clin-
ical success of HA can be attributed to the fact that it forms a bond
with both hard and soft tissues and is osteoconductive [4]. One of thex: þ44 121 414 5324.
er).
Ltd.Open access under CC BY license.drawbacks of using HA is that, in its dense form, it remains in the
body for a prolonged period following implantation [5] and its brittle
nature means that it presents a long-standing risk of catastrophic
failure [6]. Some workers have attempted to solve this problem by
incorporating macroporosity (>200 mm) to allow bone in-growth
[7]. While the original rationale behind using HA as bone re-
placements was clear, the principle itself is somewhat crude. The HA
crystallites in bone are typically nanoscopic (100 nm in length,
thickness 4e6 nm, and breadth 30e45 nm [8]) and incorporate
numerous substitutions, whereas sintered HA and b-TCP (b-trical-
cium phosphate; Ca3(PO4)2) are microcrystalline and consequently
exhibit a correspondingly low speciﬁc surface area. Furthermore,
although bone is formed of 60e70 vol% HA, the collagen matrix and
other proteins in bone play important biological and structural roles.
Therefore, other than a compositional similarity, HA bone graft
substitute typically has little mechanical or biological similarity to
bone. Consequently, a number of other groups have attempted to
L.M. Grover et al. / Biomaterials 34 (2013) 6631e66376632develop new grafting materials using other osteoconductive
calcium salts more soluble in physiological conditions such as
brushite [9e12]. Although some success has been reported, brushite
grafts tend to hydrolyse to form HA [13], which can also result in
long-term implant stability and therefore present a prolonged risk of
implant failure. There are several reports in the literature of brushite-
based calcium phosphate cements being chemically modiﬁed to
prevent the hydrolysis reaction fromoccurring. Newberryite [14], for
example, has been added to brushite cement and has been shown to
prevent hydrolysis from occurring in vitro. Unfortunately, these
results could not be reproduced in vivo [15]. We have also modiﬁed
brushite-based cements using pyrophosphoric acid as a reactant
[12,16,17]. This modiﬁcation enabled the production of a cement
containing an amorphous pyrophosphate phase, which was shown
to prevent the hydrolysis reaction for over 90 days in vitro [16].
Pyro or diphosphate ðP2O74Þ ions are inhibitors of HA crystal for-
mation and are essential in the control of biomineralisation [17e19],
their potent mineralisation inhibiting activity has been exploited to
soften water. Importantly, although pyrophosphates inhibit mineral
formation [18], active osteoblasts secrete alkalinephosphatase (ALP),
which can hydrolyse pyrophosphate ions (Equation (1)), which
simultaneously causes loss of this ion’s potent inhibiting effect onHA
formation and supersaturates the extra-cellular ﬂuid with ortho-
phosphates that induce mineralisation [19]. This mechanism has
been shown to be critical to the control of bonemineralisation.With
the exception of the highly insoluble and thermally stable phase b-
dicalcium pyrophosphate [20], the pyrophosphates are relatively
unexplored in bone graft replacement applications, despite decades
of research demonstrating the role of this ion in bone.
P2O7
4 þ H2O/2PO43 þ 2Hþ (1)
Here we have investigated whether the amorphous pyrophos-
phate phase can prevent brushite hydrolysis and consequently long-
term cement stability in vivo. Following periods of implantation,
cement samples were retrieved and characterised with respect to
compositionusing ion chromatographyandX-raydiffraction. Sections
were made of the implant site and the extent of implant resorption
was determined using histomorphometry. Finally, an in vitro model
was used to systematically evaluate how the enzyme alkaline phos-
phatase interacts with amorphous calcium pyrophosphate phase.
2. Materials and methods
2.1. Cement formulation
A systematic study was undertaken to determine the liquid compositions at
which setting pyrophosphate cements could be produced while maximising amor-
phous calcium pyrophosphate content. All cement pastes were formed from the
mixture of b-TCP (Plasma-Biotal, Derbyshire, UK), pyrophosphoric acid, orthophos-
phoric acid (SigmaeAldrich, Gillingham, UK) and double distilled water at a constant
powder to liquid ratio (P:L) of 1.50 g/mL. Cement pastes were formed where the
water constituted of between 0 and 90wt% of the liquid phase (at 5wt% increments).
At eachwater content, the proportions of pyrophosphoric and orthophosphoric acids
were varied so that every possible liquid composition (at 5 wt% increments) was
produced. To ﬁnd the ﬁnal setting times exhibited by the cements a needle (1.05mm
diameter and 454 g mass) was applied to the surface of the cement. The point at
which this needle no longer indented the surface was the ﬁnal setting time. All
measurements were made in ambient conditions and were repeated three times for
each cement formulation investigated. From the resultant data the compositions
were grouped into those that whenmixed with b-TCP (powder to liquid ratio 1.50 g/
mL) set in a.) less than 30 s, b.) 30 s to 30min, c.) 30min to less than 24 h and d.) non-
setting formulations. A ternary plot was then constructed to show the liquid com-
positions resulting in the formation of cements setting fully in these ranges. Once the
ternary plot was completed the entire experiment was repeated to ensure accuracy.
2.2. X-ray diffraction and nuclear magnetic resonance
The compositions of the hardened cements were determined using X-ray
diffraction (XRD) and nuclear magnetic resonance (NMR). Dried cement sampleswere powdered using a pestle andmortar. For XRD, the powder was placed between
two pieces of magic tape (3M, Minnesota, USA) and attached to the sample holder,
which was mounted in the X-ray diffractometer (Siemens D5000, Munich, Ger-
many). X-ray powder diffraction data were collected using Cu Ka1 radiation from a
powder X-ray diffractometer, ﬁtted with a Ge primary beam monochromator and
aligned in transmissionmode. For phase analysis each data set was collected from 5
to 100 2q with step size 0.02 , each step requiring 9 s, such that patterns required
approximately 12 h to collect. A multiphase, whole pattern Rietveld analysis using
the General Structure Analysis Suite (GSAS) of programs was employed to determine
the crystalline phase compositions of the samples. Structural models for CaH-
PO4$2H2O, CaHPO4, b-Ca3(PO4)2, b-Ca2(P2O7), Ca2P2O7$2H2O, and Ca10(PO4)6OH2
[21e26] were obtained from the literature references and a linear interpolated
background functionwas utilised, together with a pseudovoigt peak shape function.
The pyrophosphate contents of cement formulations one to elevenwere determined
by quantitative NMR of powdered cement. High-resolution solid state 31P NMR
experiments were performed at 121.51 MHz using an NMR spectrometer (CMX In-
ﬁnity 300 spectrometer, Chemagnetics, CO, USA) with a Chemagnetics 4 mm triple-
resonance magic angle spinning (MAS) probe. All spectrawere recorded using direct
polarisationwith 1H decoupling (with a decoupling ﬁeld strength of 100 kHz), magic
angle spinning (with a spinning frequency of 7000  2 Hz) and a set sample tem-
perature of 25 C. The spectra were referenced relative to 85 wt% orthophosphoric
acid at 0 ppm. To ensure that the 31P MAS NMR spectra of the cement samples were
quantitative 31P spin-lattice relaxation times (T1) were ﬁrst determined for samples
of the components of the cements using the saturation-recovery technique. The
high-resolution solid state 31P NMR spectra of the cement samples were then
recorded using a recycle delay of greater than ﬁve times the longest value T1
determined for the individual cement components. The composition of the cements
could then be determined by ﬁtting the spectra using the spectrometer software to
obtain reliable peak intensities.
2.3. Determination of orthophosphate:pyrophosphate
In order to determine the proportions of the hardened cement consisting of
orthophosphate and pyrophosphate phases, approximately 25 mg of cement were
dissolved in 100 mL nitric acid (100 mM). The resulting solution was diluted ten
times with double distilled water before analysis using an ion chromatography
system (ICS-2500, Dionex, Sunnyvale, CA, USA) equipped with an appropriate
analytical column (IonPac AS16, Dionex, Sunnyvale, CA, USA).
2.4. In vivo experimentation
To evaluate biological response to the material and cement resorption, samples
were implanted in an ovine model. The pyrophosphate modiﬁed cement used in the
study was formed by combining b-TCP with pyrophosphoric acid (540 mg) and
double distilled water (720 mg) at a powder to liquid ratio of 2.25 g/mL. The
orthophosphate brushite cement was formed by the combination of b-TCP with
orthophosphoric acid (2 M) containing trisodium citrate (50mM) at a powder to liquid
ratio of 1.75 g/mL. The cements were cast into PTFE split moulds to form hardened
cement cylinders (diameter 6.4 mm and length 12 mm). The samples were stored at
37 C and 100% relative humidity for 24 h prior to sterilisation by gamma irradiation.
The cement cylinders (four replicates per time-point) were implanted into the tibiae
of eighteen female Blue Faced Leicester cross Suffolk sheep of approximately four
years in age according to a randomisation schedule. Brieﬂy, anaesthesia was induced
with thiopentone sodium (5%) which was administered ‘to effect’ by intravenous
injection. An incision was made in the medial side of the proximal tibia. A defect
(6.4 mm diameter, 12 mm deep) was then created with an orthopaedic drill, with at
least one intermediate-sized drill used to reduce the chance of thermal necrosis to
the bone. Bone debris was removed by saline irrigation and the defect ﬂushed with
local anaesthetic. The defects were ﬁlled with test material according to the ran-
domisation schedule. To enable the location of the defect site two K-wires were
inserted either side of it. Each K-wire was implanted at a distance of approximately
8 mm from the centre of the implant so that the wires and the centre of the implant
were aligned in a straight-line. The K-wires were inserted at a depth not greater than
30 mm. This procedure was then repeated in the bilateral leg. The muscle, fascia,
subcutaneous tissue and skin were closed in a standard surgical manner using
resorbable sutures. Calcein was administered 24e48 h (10 mg/kg) after surgery.
Alizarin C-one marker was administered at one, two and four months following
implantation in the sheep (30 mg/kg) for the three, six and twelve month time-
points, respectively. Oxytetracycline was given (30 mg/kg) one week prior to sacri-
ﬁce. All animals were euthanised using Pentoject. Following gross pathology ob-
servations the implant site/tibial plateau was removed and the surrounding bone
trimmed down. Some surrounding undamaged bone was retained so that histolog-
ical analysis of the undamaged bone could be performed. All samples were ﬁxed in
alcohol (70%) at 4 C. The implants were then bisected into two halves using a low-
speed diamond saw. The cortical half of the explant was embedded into a methyl
methacrylate resin. The resin blocks were sectioned using the Leica diamond
microtome saw. Sections were cut (200 mm thickness) and adhered to plastic slides.
The sections were ground down to approximately 100 mm. Two resin sections were
prepared, one for evaluation by ﬂuorescent microscopy, the other was stained with
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Fig. 1. a. A ternary liquid-composition setting diagram. The cements were grouped ac-
cording to their setting times and eleven cement formulations (marked on the diagram)
were selected for compositional characterisation using NMR. b. The proportions of
cement formulations 1e11 comprised by pyrophosphate and orthophosphate compo-
nents. In the case of the cement formulations consisting of<55wt% pyrophosphoric acid
(marked 4e11) an increase in the concentration of pyrophosphoric acid resulted in an
increase in the proportion of amorphous calcium pyrophosphate precipitated. However,
in the case of the cements formed liquid components containing pyrophosphoric acid
concentrations higher than 78 wt% (marked 1e3) there was no calcium pyrophosphate
formed, rather the cement consisted of MCPM, which was probably precipitated as a
result of the low pH and calcium to phosphorus ratio of the cement mix.
L.M. Grover et al. / Biomaterials 34 (2013) 6631e6637 6633alizarin red and used to evaluate bone growth. Image capture was performed using
the using the Leica FLZ III Stereomicroscope coupled to a JVC digital camera
(KY-F1030). Images of normal trabecular bone (stained with alizarin red) were also
captured. These were used to calculate the area of bone that would be observed in a
defect that had undergone complete repair. Image analysis of the alizarin red stained
sections was carried out using Image-Pro Plus version 5.0 software. Calibration was
performed using a 10mm graticule as follows. Measurements were performed using
a colour segmentation technique presuming the diameter of the original implant to
be 6.4 mm. Newly formed bone was coloured green. Following colour segmentation,
the proportion of new bone was determined using Excel (Microsoft, USA).
2.5. In vitro evaluation of amorphous calcium pyrophosphate dissolution
Synthesis of amorphous Ca2P2O7$4H2O was achieved using a precipitation re-
action involving the addition of 200 mL of a 0.2 mol L1 solution of potassium py-
rophosphate (K4P2O7$3H2O, Sigma Aldrich, Gillingham, UK, 97% purity) to 200 mL of
1.0 mol L1 calcium chloride (CaCl2$2H2O, Sigma Aldrich, Gillingham, UK, 97% pu-
rity) aqueous solution under vigorous stirring at room temperature [27].
In vitro experimentation was undertaken to evaluate the interaction between
amorphous calcium pyrophosphate and ALP enzyme. 10 mg of amorphous calcium
pyrophosphate was incubated with 20 U ALP (Sigma Aldrich, Gillingham, UK) in
10 mL Tris HCL (SigmaeAldrich, Gillingham, UK) solution. The solutions were placed
in a water bath at 37 C under vigorous stirring. The concentration of PO4
3 ion
released into solution was determined by ICP. The samples were taken every 15 min
in the ﬁrst hour and every hour for the remaining 6 h. 1 mL of the solution was
removed before the medium was centrifuged at 1000 r/min for 2 min, then 1 mL of
Tris HCL solution with the same concentration of ALP was then added to the me-
dium. For ICP detection, all the samples were diluted to 5 mL using distilled water
before testing. For comparison, the experiment was done in the Tris HCL solution
without ALP under the same condition.
3. Results
3.1. Cement formulation parameters
A systematic study was undertaken to identify liquid composi-
tions that facilitated the production of cements that exhibited
clinically relevant setting times of between 30 s and 30 min. The
resulting data was aggregated to form a ternary liquid composition
diagram (Fig. 1a). There were two distinct regions in which the
liquid compositions allowed setting in 30 se30 min. The material
produced using >60 wt% pyrophosphoric acid dispersed on im-
mersion inwater. The set cements contained varying proportions of
brushite, monocalcium phosphate monohydrate (MCPM), mone-
tite, unreacted b-TCP and a hydrated calcium pyrophosphate. The
presence of the calcium pyrophosphate was detected by nuclear
magnetic resonance (NMR) (Fig. 1b) and ion chromatography, but
was not detected by X-ray diffraction (XRD), suggesting that it
exhibited an amorphous structure. Depending on liquid composi-
tion either purely orthophosphate (1e3) or pyrophosphate (4e11)
containing matrices were formed (Fig. 1a,b (1e3) and (4e11),
respectively). Formulations 1e3 were shown to consist entirely of
MCPM and so were excluded from further study. By further opti-
mising the cement formulation, it was possible to produce a ma-
terial that consisted of as much as 28 wt% amorphous calcium
pyrophosphate (Fig.1b) and yet exhibited a compressive strength of
25  2 MPa, in the same magnitude as cancellous bone and other
inorganic bone cements [28].
3.2. In vivo experimentation
The cement formulation which consisted of the highest pro-
portion of amorphous calcium pyrophosphate (28 wt%) was
implanted into the proximal tibia in the hind legs of sheep for
periods of three, six and twelve months after which the degrada-
tion of the pyrophosphate cement and bone formation were
compared with an orthophosphate cement and a trabecular bone
control. The orthophosphate control cement was initially resorbed
and replaced by new bone at a similar rate to the pyrophosphate
cement (Fig. 2a and b) (6 and 5 area% new bone respectively) withthe formation of a layer of new bone across the surface of each
material. Following six and twelve months of implantation, how-
ever, little further reduction in the area of the orthophosphate
cement was noted and consequently the proportion of new bone
formed in the defect was limited (14 area% after 12 months). The
cement remained as a dense core in the centre of the bone defect.
This was in contrast to the pyrophosphate cement, which degraded
at a similar rate over the ﬁrst three months of the study (replaced
by 5 area% new bone), but over the remainder of the study
continued to degrade from it’s periphery and was replaced with
newly formed bone. Following 12 months the pyrophosphate
cement had degraded more extensively than the orthophosphate
cement, with the formation of 33 area% new bone, which was
comparable with natural trabecular bone (24e36 area%, Fig. 2b).
The surface of the cement core was crenellated with evidence of
new bone formation in regions of ceramic degradation.
3.3. Compositional change during degradation studies
In order to determine the origin of the difference in degradation
behaviour, the compositions of the retrieved cement implants were
characterised using a combination of XRD and ion chromatography.
XRD data (Fig. 3) showed that the orthophosphate cement con-
tained minimal brushite in the defect after three months, with the
Fig. 2. a. Histological sections through the implanted cement and surrounding bone. The alizarin red stained sections through the orthophosphate and pyrophosphate modiﬁed
brushite cement following implantation in the tibia of a sheep for three, six and twelve months. In all cases the original cancellous bone is stained in red, new bone in green pseudo-
colouring and the cement is unstained. b. The percentage area of new bone in the cement cavity following implantation for 3, 6 and 12 months. The error bars shown represent the
standard error in each condition. (For interpretation of the references to colour in this ﬁgure legend, the reader is referred to the web version of this article.)
L.M. Grover et al. / Biomaterials 34 (2013) 6631e66376634only apparent crystalline phase being b-TCP. In contrast, the pyro-
phosphate modiﬁed cement contained signiﬁcant amounts of
brushite even after twelve months. The calcium pyrophosphate
content of the ceramic was determined after each time-point and
this work demonstrated that the weight fraction of the material
that constituted calcium pyrophosphate diminished until after 12
months the proportion of material contributed by calcium pyro-
phosphate reduced to 30 wt% of the starting value (Fig. 4). This
reduction in the proportion of cement contributed by the calcium
pyrophosphate phase demonstrates that it was preferentially dis-
solved from the implanted material. To determine whether this
preferential dissolution of calcium pyrophosphate could be attrib-
uted to enzyme mediated pyrophosphate hydrolysis, an in vitro
experiment was undertaken where an amorphous calcium pyro-
phosphate (as synthesised in accordance with the method of Slater
et al. [27]) was exposed to ALP. The resulting data clearly demon-
strated an increase in the concentration of PO4
3 ions in the
presence of ALP (Fig. 5a) thus conﬁrming the pyrophosphate
released into solution was cleaved to form orthophosphate ions as
compared with the control buffer solution. Interestingly, these high
levels of phosphate and calcium ions should provide for local su-
persaturation with respect to hydroxyapatite precipitation, how-
ever our animal studies indicate that any such precipitation appearsto have occurred within the natural process of new bone deposition
and not as isolated HA deposits. To identify whether or not this
process was surface mediated, an experiment was undertaken
whereby calcium pyrophosphate dihydrate crystals were aged
within a visking tubing that prevented the access of ALP to the
surface of the calcium pyrophosphate crystals (Fig. 5b). Even when
ALP was isolated from the surface of the crystal, there was a notable
acceleration in dissolution when compared with the control, sug-
gesting that this process was not surface mediated.
4. Discussion
Sparingly soluble calcium phosphate salts have been widely
investigated for application as resorbable bone replacement ma-
terials. b-TCP forms the basis of a number of commercially available
bone graft replacements [2], but as it does not form in ambient
conditions, it is not widely used for reconstruction following
trauma. Calcium phosphate cements can harden to form a matrix
that consists, in the most part, of brushite [10,11]. As this material is
several orders of magnitude more soluble than hydroxyapatite, it
can be resorbed by a combination of cell-mediated degradation and
simple dissolution [15]. The metastable nature of the salt, however,
means that it has been shown to hydrolyse to form a poorly
Fig. 3. X-ray diffraction patterns of the orthophosphate and pyrophosphate brushite
cements following implantation for 0 and 12 months. Peaks that are marked with an *
indicate the presence of brushite in the cement matrix. Reﬂection markers for brushite
(upper) and b-TCP (lower) are also included. The pyrophosphate modiﬁed cement
contained brushite following 12 months of ageing, whereas the orthophosphate
brushite cement did not.
Fig. 5. The action of ALP on pyrophosphate ions accelerating calcium pyrophosphate
dissolution. a. Orthophosphate concentration in solution over a period of 6 h immer-
sion. Amorphous calcium pyrophosphate was immersed in ALP and non-ALP con-
taining solutions (Control), and dissolution was monitored. In the presence of ALP, the
phosphate concentration was substantially higher than in its absence indicating that
ALP acted to accelerate dissolution. b. Calcium pyrophosphate crystal dissolution when
ALP has or does not have access to the crystal surface. There was no difference in
crystal dissolution when ALP was separated from the cement surface by a visking
tubing (Control) and had access to the surface (ALP) suggesting that the accelerated
dissolution process was not surface mediated.
L.M. Grover et al. / Biomaterials 34 (2013) 6631e6637 6635crystalline hydroxyapatite which slows or prevents resorption
in vitro and in vivo [13,15,16]. Efforts have been made to inhibit this
hydrolysis reaction and prevent long-term stability of the grafts, for
example, by adding a magnesium salt (Newberryite) into the
hardened matrix [14]. These approaches, however, have had no
success in preventing long-term stability in vivo. We have previ-
ously reported the formulation of a material using combination of a
sparingly soluble calcium phosphate (a-TCP, b-TCP or TTCP) and a
condensed phosphoric acid [12,15] to form an amorphous calcium
pyrophosphate in the cement matrix. This material was shown to
be resistant to hydrolysis over a period of 90 days of ageing using an
in vitromodel [16]. Herewe have demonstrated that this material is
not only resistant to hydrolysis, but also seems to stimulate bone
generation around the implant.
Over the course of the study, the amorphous calcium pyro-
phosphate in the pyrophosphate cement effectively prevented
brushite hydrolysis. As the pyrophosphate cement was more
extensively resorbed than the orthophosphate cement control, we
may speculate that the signiﬁcant hydrolysis of brushite to less0
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Fig. 4. The quantity of calcium pyrophosphate in the pyrophosphate modiﬁed brushite
cement after 0, 3, 6 and 12 months of implantation. Although there was a steady
reduction in the quantity of amorphous calcium pyrophosphate present in the cement
with time, there was no deleterious effect on the deposition of new bone. In vitro
experiments conﬁrmed that as the pyrophosphate ions were released into solution,
they were broken down by ALP, an enzyme with a known pyrophosphatase function.resorbable material, such as poorly crystalline HA, may explain the
reduced resorption of the orthophosphate cement. Pyrophosphate
ions have long been identiﬁed as potent inhibitors of apatite for-
mation in vivo [18], a ﬁnding that led to the use of hydrolysis resis-
tant phosphonate analogues as effective osteoporosis treatments
[29], and even today a confusion exists between inhibiting apatite
formation in vitro and inhibiting bone formation in vivo, since in
addition to poisoning apatite nucleation, they have also been shown
to cause the apoptosis of osteoclast (bone resorbing) cells [30,31]. In
the presence of ALP (as released by active osteoblasts), however,
pyrophosphate ions are hydrolysed (Equation (1)), which can result
in localised saturation with respect to phosphate ions resulting in
mineral deposition [18,19]. Such an effect seems to have been in
operation here, since despite the fact that a steady reduction in the
quantity of amorphous calcium pyrophosphate was noted in the
cement with time (Fig. 4), considerably more new bone was formed
in the defect ﬁlled with the pyrophosphate cement than in the
orthophosphate cement or the trabecular control (Fig. 2a).
Other groups have investigated the use of higher chain calcium
polyphosphate ceramics as bone graft replacements [32,33], how-
ever, the potential drawback with these materials is that as
degradation occurs the tripolyphosphate ions ðP3O105Þ are broken
down to form one orthophosphate anion and one pyrophosphate
anion (Equation (2)). The continuous production of pyrophosphate
L.M. Grover et al. / Biomaterials 34 (2013) 6631e66376636anions during the dissolution of calcium polyphosphate could ul-
timately interferewith the deposition of new bone andmay explain
why these materials have not found widespread clinical use.
P3O10
5 þH2O/PO43 þ P2O74 þ 2Hþ (2)
These previously reported calcium polyphosphate materials
[32,33] are also of signiﬁcantly lower solubility than the amorphous
materials deposited within the cement matrix. Consequently, one
might expect a slower rate of dissolution into the surrounding
media. This also may suggest that the ALP interacts with condensed
phosphates that are in solution and not when they are bound in a
solid form, which is contrary to previous reports, which have
shown that ALP is capable of binding to calcium pyrophosphate
salts and to some extent can mediate crystal dissolution [34]. To
test this hypothesis, in vitro experiments were performed where
ALP was exposed directly to calcium pyrophosphate and separated
from the surface by a semipermeable membrane. These experi-
ments showed no difference between extents of degradation when
the ALP did or did not have access to the crystal surface. This sug-
gests that the binding of ALP to the surface of the calcium pyro-
phosphate material was not a signiﬁcant factor (Fig. 5b) and that
the accelerated dissolution of the amorphous calcium pyrophos-
phate salt occurs as a result of Le Chatelier’s principle, whereby the
removal of pyrophosphate ions from solution, and the subsequent
removal of orthophosphate by mineralisation, drive forward the
dissolution process (Equation (3)).
Ca2P2O7,4H2O#2Ca
2þðaqÞ þ P2O74ðaqÞ
þ 4H2O#
ALP
2Ca2þðaqÞ þ 2PO43ðaqÞ þ 3H2Oþ 2Hþ (3)Fig. 6. A schematic diagram illustrating the enzyme mediated degradation and bone
formation around the pyrophosphate modiﬁed brushite cement. Following implanta-
tion, the ceramic material forms an intimate attachment to surrounding bone (upper
diagram). Osteoblasts line the surface of the surrounding trabecular bone and their
plasma membranes are enriched with respect to ALP (central diagram). As the pyro-
phosphate ions are dissolved from the cement, they are cleaved by the ALP, which
decreases saturation with respect to calcium pyrophosphate and enhances cement
dissolution. As the cleavage process also results in supersaturation with respect to HA,
new bone formation occurs in the place of the degraded ceramic. After 12 months of
implantation there is an extensive cement degradation and new bone formation.The release of condensed phosphates from amorphous granules
and their subsequent hydrolysis by ALP has been proposed to be the
mechanism by which bone mineralisation occurs in the body [35]
and this method has been used to induce mineralisation within
collagen gels [36]. It is possible, therefore, that this material ex-
ploits this biological process to enhance bone deposition. We can
surmise that the incorporation of amorphous calcium pyrophos-
phate in bone replacement materials may be an effective way of
delivering pyrophosphate species to the locality of the implant/new
bone interface. These pyrophosphate species may then be cleaved
by the osteoblast associated enzyme (ALP) to provide enzymatically
controlled levels of the inorganic components for mineralisation
(Fig. 6).5. Conclusion
Here we have demonstrated that the modiﬁcation of calcium
phosphate biomaterials with amorphous calcium pyrophosphate
can effectively enhance the rate of bone formation in vivo. The
amorphous pyrophosphate phase acted to prevent long-term sta-
bility by inhibiting brushite conversion to hydroxyapatite. The py-
rophosphate was preferentially dissolved from the hardened
ceramic material and an in vitromodel demonstrated that this was
due to accelerated dissolution through cleavage by enzymes with
pyrophosphatase activity. The localised removal of the pyrophos-
phate ions was associated with supersaturation with respect to
hydroxyapatite and this was shown to aid bonemineralisation. This
is the ﬁrst example of a cement bone replacement, that contains a
phase that may act as a substrate for an enzyme associated with the
mineralisation process and can thereby enhance bone accrual. This
represents a change in focus in the development of ceramic bone
graft replacements, by designing a material to induce a speciﬁc
biological reaction, rather than implanting a material that mimics a
component of a biological structure with little interaction with
biological processes at the implant site.Acknowledgements
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